Advertisement

Scleroderma in the Elderly Population

  • Rebecca L. MannoEmail author
  • Fredrick M. Wigley
Chapter

Abstract

Scleroderma has a median age of onset in the fifth decade of life; however, there are many individuals who develop scleroderma later or who are aging with this disease. It is important that clinicians are able to recognize features of scleroderma in the elderly and distinguish these from well-established imitators. The age of scleroderma onset can impact the course of disease and increase the risk for organ-specific complications such as pulmonary vascular disease. As individuals age with scleroderma, physicians should focus on careful monitoring of each organ system and comprehensive medical care. Treatment principles should be customized to an individual’s disease, and the importance of nutrition, mobility, and social support emphasized.

Keywords

Scleroderma Systemic sclerosis Raynaud’s phenomenon Elderly Late-age onset 

References

  1. 1.
    Wigley FM, Hummers LK. Clinical features of systemic sclerosis. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, editors. Rheumatology. 3rd ed. New York: Mosby; 2003. p. 1463–79.Google Scholar
  2. 2.
    LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger Jr TA, et al. Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis. J Rheumatol. 1988;15(2):202–5.PubMedGoogle Scholar
  3. 3.
    Medsger Jr TA, Masi AT, Rodnan GP, Benedek TG, Robinson H. Survival with systemic sclerosis (scleroderma). A life-table analysis of clinical and demographic factors in 309 patients. Ann Intern Med. 1971;75(3):369–76.PubMedGoogle Scholar
  4. 4.
    Jacobsen S, Halberg P, Ullman S. Mortality and causes of death of 344 danish patients with systemic sclerosis (scleroderma). Br J Rheumatol. 1998;37(7):750–5.PubMedCrossRefGoogle Scholar
  5. 5.
    Mayes MD, Reveille JH. Epidemiology, demographics, and genetics. In: Clements PJ, Furst DE, editors. Systemic sclerosis. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2004.Google Scholar
  6. 6.
    Scalapino K, Arkachaisri T, Lucas M, Fertig N, Helfrich DJ, Londino Jr AV, et al. Childhood onset systemic sclerosis: Classification, clinical and serologic features, and survival in comparison with adult onset disease. J Rheumatol. 2006;33(5):1004–13.PubMedGoogle Scholar
  7. 7.
    Steen VD, Medsger Jr TA. Epidemiology and natural history of systemic sclerosis. Rheum Dis Clin North Am. 1990;16(1):1–10.PubMedGoogle Scholar
  8. 8.
    Derk CT, Artlett CM, Jimenez SA. Morbidity and mortality of patients diagnosed with systemic sclerosis after the age of 75: A nested case-control study. Clin Rheumatol. 2006;25(6):831–4.PubMedCrossRefGoogle Scholar
  9. 9.
    Systemic sclerosis in old age. Br Med J. 1979 Nov 24;2(6201):1313–4.Google Scholar
  10. 10.
    Maricq HR, Carpentier PH, Weinrich MC, Keil JE, Franco A, Drouet P, et al. Geographic variation in the prevalence of raynaud’s phenomenon: Charleston, SC, USA, vs tarentaise, savoie, france. J Rheumatol. 1993;20(1):70–6.PubMedGoogle Scholar
  11. 11.
    Smolander J. Effect of cold exposure on older humans. Int J Sports Med. 2002;23(2):86–92.PubMedCrossRefGoogle Scholar
  12. 12.
    Planchon B, Pistorius MA, Beurrier P, De Faucal P. Primary raynaud’s phenomenon. age of onset and pathogenesis in a prospective study of 424 patients. Angiology. 1994;45(8):677–86.PubMedCrossRefGoogle Scholar
  13. 13.
    Kallenberg CG, Wouda AA, Hoet MH, van Venrooij WJ. Development of connective tissue disease in patients presenting with raynaud’s phenomenon: A six year follow up with emphasis on the predictive value of antinuclear antibodies as detected by immunoblotting. Ann Rheum Dis. 1988;47(8):634–41.PubMedCrossRefGoogle Scholar
  14. 14.
    Kallenberg CG. Early detection of connective tissue disease in patients with raynaud’s phenomenon. Rheum Dis Clin North Am. 1990;16(1):11–30.PubMedGoogle Scholar
  15. 15.
    Ling SM, Wigley FM. Raynaud’s phenomenon in older adults: Diagnostic considerations and management. Drugs Aging. 1999;15(3):183–95.PubMedCrossRefGoogle Scholar
  16. 16.
    Friedman EI, Taylor Jr LM, Porter JM. Late-onset raynaud’s syndrome: diagnostic and therapeutic considerations. Geriatrics. 1988;43(12):59,63, 67–70.PubMedGoogle Scholar
  17. 17.
    Grassi W, Medico PD, Izzo F, Cervini C. Microvascular involvement in systemic sclerosis: Capillaroscopic findings. Semin Arthritis Rheum. 2001;30(6):397–402.PubMedCrossRefGoogle Scholar
  18. 18.
    Kabasakal Y, Elvins DM, Ring EF, McHugh NJ. Quantitative nailfold capillaroscopy findings in a population with connective tissue disease and in normal healthy controls. Ann Rheum Dis. 1996;55(8):507–12.PubMedCrossRefGoogle Scholar
  19. 19.
    Ho M, Veale D, Eastmond C, Nuki G, Belch J. Macrovascular disease and systemic sclerosis. Ann Rheum Dis. 2000;59(1):39–43.PubMedCrossRefGoogle Scholar
  20. 20.
    Stafford L, Englert H, Gover J, Bertouch J. Distribution of macrovascular disease in scleroderma. Ann Rheum Dis. 1998;57(8):476–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Wigley FM. Clinical practice. raynaud’s phenomenon. N Engl J Med. 2002;347(13):1001–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Schachna L, Wigley FM, Chang B, White B, Wise RA, Gelber AC. Age and risk of pulmonary arterial hypertension in scleroderma. Chest. 2003;124(6):2098–104.PubMedCrossRefGoogle Scholar
  23. 23.
    Champion HC. The heart in scleroderma. Rheum Dis Clin North Am. 2008;34(1):181,90; viii.Google Scholar
  24. 24.
    Boin F, Hummers LK. Scleroderma-like fibrosing disorders. Rheum Dis Clin North Am. 2008;34(1):199,220; ix.Google Scholar
  25. 25.
    Foti R, Leonardi R, Rondinone R, Di Gangi M, Leonetti C, Canova M, et al. Scleroderma-like disorders. Autoimmun Rev. 2008;7(4):331–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Blum M, Wigley FM, Hummers LK. Scleromyxedema: A case series highlighting long-term outcomes of treatment with intravenous immunoglobulin (IVIG). Medicine (Baltimore). 2008;87(1):10–20.CrossRefGoogle Scholar
  27. 27.
    Gabriel SE, Perry HO, Oleson GB, Bowles CA. Scleromyxedema: A scleroderma-like disorder with systemic manifestations. Medicine (Baltimore). 1988;67(1):58–65.Google Scholar
  28. 28.
    Dziadzio M, Anastassiades CP, Hawkins PN, Potter M, Gabrielli A, Brough GM, et al. From scleredema to AL amyloidosis: Disease progression or coincidence? review of the literature. Clin Rheumatol. 2006;25(1):3–15.PubMedCrossRefGoogle Scholar
  29. 29.
    Dispenzieri A. POEMS syndrome. Blood Rev. 2007;21(6):285–99.PubMedCrossRefGoogle Scholar
  30. 30.
    Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Hematol Oncol Clin North Am. 2007;21(6):1093,113, ix.Google Scholar
  31. 31.
    Naschitz JE, Rosner I, Rozenbaum M, Zuckerman E, Yeshurun D. Rheumatic syndromes: Clues to occult neoplasia. Semin Arthritis Rheum. 1999;29(1):43–55.PubMedCrossRefGoogle Scholar
  32. 32.
    Haroon M, Phelan M. A paraneoplastic case of palmar fasciitis and polyarthritis syndrome. Nat Clin Pract Rheumatol. 2008;4(5):274–7.PubMedCrossRefGoogle Scholar
  33. 33.
    Sheehy C, Ryan JG, Kelly M, Barry M. Palmar fasciitis and polyarthritis syndrome associated with non-small-cell lung carcinoma. Clin Rheumatol. 2007;26(11):1951–3.PubMedCrossRefGoogle Scholar
  34. 34.
    Martorell EA, Murray PM, Peterson JJ, Menke DM, Calamia KT. Palmar fasciitis and arthritis syndrome associated with metastatic ovarian carcinoma: A report of four cases. J Hand Surg Am. 2004;29(4):654–60.PubMedCrossRefGoogle Scholar
  35. 35.
    Naschitz JE, Misselevich I, Rosner I, Yeshurun D, Weiner P, Amar M, et al. Lymph-node-based malignant lymphoma and reactive lymphadenopathy in eosinophilic fasciitis. Am J Med Sci. 1999;318(5):343–9.PubMedCrossRefGoogle Scholar
  36. 36.
    Khanna D, Verity A, Grossman JM. Eosinophilic fasciitis with multiple myeloma: A new haematological association. Ann Rheum Dis. 2002;61(12):1111–2.PubMedCrossRefGoogle Scholar
  37. 37.
    Philpott H, Hissaria P, Warrren L, Singhal N, Brown M, Proudman S, et al. Eosinophilic fasciitis as a paraneoplastic phenomenon associated with metastatic colorectal carcinoma. Australas J Dermatol. 2008;49(1):27–9.PubMedCrossRefGoogle Scholar
  38. 38.
    Antic M, Lautenschlager S, Itin PH. Eosinophilic fasciitis 30 years after – what do we really know? report of 11 patients and review of the literature. Dermatology. 2006;213(2):93–101.PubMedCrossRefGoogle Scholar
  39. 39.
    Lakhanpal S, Ginsburg WW, Michet CJ, Doyle JA, Moore SB. Eosinophilic fasciitis: Clinical spectrum and therapeutic response in 52 cases. Semin Arthritis Rheum. 1988;17(4):221–31.PubMedCrossRefGoogle Scholar
  40. 40.
    Naschitz JE, Boss JH, Misselevich I, Yeshurun D, Rosner I. The fasciitis-panniculitis syndromes. clinical and pathologic features. Medicine (Baltimore). 1996;75(1):6–16.Google Scholar
  41. 41.
    Baumann F, Bruhlmann P, Andreisek G, Michel BA, Marincek B, Weishaupt D. MRI for diagnosis and monitoring of patients with eosinophilic fasciitis. AJR Am J Roentgenol. 2005;184(1):169–74.PubMedGoogle Scholar
  42. 42.
    Cowper SE. Nephrogenic systemic fibrosis: An overview. J Am Coll Radiol. 2008;5(1):23–8.PubMedCrossRefGoogle Scholar
  43. 43.
    Ting WW, Stone MS, Madison KC, Kurtz K. Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol. 2003;139(7):903–6.PubMedCrossRefGoogle Scholar
  44. 44.
    Prchal D, Holmes DT, Levin A. Nephrogenic systemic fibrosis: The story unfolds. Kidney Int. 2008;73(12):1335–7.PubMedCrossRefGoogle Scholar
  45. 45.
    Information on gadolinium-containing contrast agents [homepage on the Internet]. Center for Drug Evaluation and Research, United States Food and Drug Administration. Available from: http://www.fda.gov/cder/drug/InfoSheets/HCP/gcca_200705.htm.
  46. 46.
    Krishnan E, Furst DE. Systemic sclerosis mortality in the united states: 1979–1998. Eur J Epidemiol. 2005;20(10):855–61.PubMedCrossRefGoogle Scholar
  47. 47.
    Scussel-Lonzetti L, Joyal F, Raynauld JP, Roussin A, Rich E, Goulet JR, et al. Predicting mortality in systemic sclerosis: Analysis of a cohort of 309 french canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine (Baltimore). 2002;81(2):154–67.CrossRefGoogle Scholar
  48. 48.
    Chung L, Krishnan E, Chakravarty EF. Hospitalizations and mortality in systemic sclerosis: Results from the nationwide inpatient sample. Rheumatology (Oxford). 2007;46(12):1808–13.CrossRefGoogle Scholar
  49. 49.
    Simeon CP, Armadans L, Fonollosa V, Solans R, Selva A, Villar M, et al. Mortality and prognostic factors in spanish patients with systemic sclerosis. Rheumatology (Oxford). 2003;42(1):71–5.CrossRefGoogle Scholar
  50. 50.
    Mayes MD, Lacey Jr JV, Beebe-Dimmer J, Gillespie BW, Cooper B, Laing TJ, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum. 2003;48(8):2246–55.PubMedCrossRefGoogle Scholar
  51. 51.
    Czirjak L, Kumanovics G, Varju C, Nagy Z, Pakozdi A, Szekanecz Z, et al. Survival and causes of death in 366 hungarian patients with systemic sclerosis. Ann Rheum Dis. 2008;67(1):59–63.PubMedCrossRefGoogle Scholar
  52. 52.
    Steen VD. The many faces of scleroderma. Rheum Dis Clin North Am. 2008;34(1):1,15; v.Google Scholar
  53. 53.
    Steen VD, Medsger Jr TA. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum. 2000;43(11):2437–44.PubMedCrossRefGoogle Scholar
  54. 54.
    Benan M, Hande I, Gul O. The natural course of progressive systemic sclerosis patients with interstitial lung involvement. Clin Rheumatol. 2007;26(3):349–54.PubMedCrossRefGoogle Scholar
  55. 55.
    Steen VD, Medsger Jr TA. Improvement in skin thickening in systemic sclerosis associated with improved survival. Arthritis Rheum. 2001;44(12):2828–35.PubMedCrossRefGoogle Scholar
  56. 56.
    Shah AA, Wigley FM, Hummers LK. Telangiectases in scleroderma: A potential clinical marker of pulmonary arterial hypertension. J Rheumatol. 2010;37(1):98–104.PubMedCrossRefGoogle Scholar
  57. 57.
    Walker UA, Tyndall A, Czirjak L, Denton C, Farge-Bancel D, Kowal-Bielecka O, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: A report from the EULAR scleroderma trials and research group database. Ann Rheum Dis. 2007;66(6):754–63.PubMedCrossRefGoogle Scholar
  58. 58.
    Chang B, Wigley FM, White B, Wise RA. Scleroderma patients with combined pulmonary hypertension and interstitial lung disease. J Rheumatol. 2003;30(11):2398–405.PubMedGoogle Scholar
  59. 59.
    Trad S, Amoura Z, Beigelman C, Haroche J, Costedoat N, le Boutin TH, et al. Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease. Arthritis Rheum. 2006;54(1):184–91.PubMedCrossRefGoogle Scholar
  60. 60.
    Clements PJ, Lachenbruch PA, Furst DE, Paulus HE, Sterz MG. Cardiac score. A semiquantitative measure of cardiac involvement that improves prediction of prognosis in systemic sclerosis. Arthritis Rheum. 1991;34(11):1371–80.PubMedCrossRefGoogle Scholar
  61. 61.
    Satoh M, Tokuhira M, Hama N, Hirakata M, Kuwana M, Akizuki M, et al. Massive pericardial effusion in scleroderma: A review of five cases. Br J Rheumatol. 1995;34(6):564–7.PubMedCrossRefGoogle Scholar
  62. 62.
    Rankin AC. Arrhythmias in systemic sclerosis and related disorders. Card Electrophysiol Rev. 2002;6(1–2):152–4.PubMedCrossRefGoogle Scholar
  63. 63.
    Follansbee WP, Zerbe TR, Medsger Jr TA. Cardiac and skeletal muscle disease in systemic sclerosis (scleroderma): A high risk association. Am Heart J. 1993;125(1):194–203.PubMedCrossRefGoogle Scholar
  64. 64.
    Akram MR, Handler CE, Williams M, Carulli MT, Andron M, Black CM, et al. Angiographically proven coronary artery disease in scleroderma. Rheumatology (Oxford). 2006;45(11):1395–8.CrossRefGoogle Scholar
  65. 65.
    Alexander EL, Firestein GS, Weiss JL, Heuser RR, Leitl G, Wagner Jr HN, et al. Reversible cold-induced abnormalities in myocardial perfusion and function in systemic sclerosis. Ann Intern Med. 1986;105(5):661–8.PubMedGoogle Scholar
  66. 66.
    Systemic sclerosis. 2nd ed. In: Clements PJ and Furst DE, editors. Philadelphia, PA: Lippincott Williams & Wilkins; 2004.Google Scholar
  67. 67.
    Wigley F, Hummers LK. Management: holistic approach to systemic sclerosis. In: Clements PJ, Furst DE, editors. Systemic sclerosis. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2004.Google Scholar
  68. 68.
    Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354(25):2655–66.PubMedCrossRefGoogle Scholar
  69. 69.
    Rubin LJ. Treatment of pulmonary arterial hypertension due to scleroderma: challenges for the future. Rheum Dis Clin North Am. 2008;34(1):191,7; viii.Google Scholar
  70. 70.
    Nihtyanova SI, Denton CP. Current approaches to the management of early active diffuse scleroderma skin disease. Rheum Dis Clin North Am. 2008;34(1):161,79; viii.Google Scholar
  71. 71.
    Gelber AC, Wigley FM. Treatment of scleroderma. Curr Opin Rheumatol. 1995;7(6):551–9.PubMedCrossRefGoogle Scholar
  72. 72.
    Roca RP, Wigley FM, White B. Depressive symptoms associated with scleroderma. Arthritis Rheum. 1996;39(6):1035–40.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Johns Hopkins UniversityBaltimoreUSA

Personalised recommendations